Published in J Cardiovasc Electrophysiol on April 21, 2008
Prognostic value of signal-averaged electrocardiogram in Chagas disease. J Cardiovasc Electrophysiol (2008) 1.74
Chagas disease. Lancet (2010) 10.25
Development and validation of a risk score for predicting death in Chagas' heart disease. N Engl J Med (2006) 6.00
Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med (2015) 5.31
Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA (2007) 5.22
American trypanosomiasis (Chagas disease). Infect Dis Clin North Am (2012) 2.04
Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation (2007) 1.99
Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J (2008) 1.99
The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz (2009) 1.54
Should tissue Doppler echocardiography be used to improve prediction of mortality risk in patients with Chagas cardiomyopathy? Int J Cardiol (2011) 1.38
Cardiac involvement with parasitic infections. Clin Microbiol Rev (2010) 1.32
Another disappointing result with implantable cardioverter-defibrillator therapy in patients with Chagas disease. Europace (2013) 1.08
[Guidelines for the evaluation and treatment of patients with cardiac arrhythmias]. Arq Bras Cardiol (2003) 1.06
Chagas heart disease: pathophysiologic mechanisms, prognostic factors and risk stratification. Mem Inst Oswaldo Cruz (2009) 1.05
Deficient regulatory T cell activity and low frequency of IL-17-producing T cells correlate with the extent of cardiomyopathy in human Chagas' disease. PLoS Negl Trop Dis (2012) 1.03
Cell therapy in Chagas cardiomyopathy (Chagas arm of the multicenter randomized trial of cell therapy in cardiopathies study): a multicenter randomized trial. Circulation (2012) 0.98
Infection by Trypanosoma cruzi metacyclic forms deficient in gp82 but expressing a related surface molecule, gp30. Infect Immun (2003) 0.98
Posaconazole versus benznidazole for chronic Chagas' disease. N Engl J Med (2014) 0.98
Trypanosoma cruzi surface molecule gp90 downregulates invasion of gastric mucosal epithelium in orally infected mice. Microbes Infect (2005) 0.98
Letter by Rassi and Rassi regarding article, "Ten-year incidence of Chagas cardiomyopathy among asymptomatic, Trypanosoma cruzi-seropositive former blood donors". Circulation (2013) 0.97
Detection of parasitemia profiles by blood culture after treatment of human chronic Trypanosoma cruzi infection. Parasitol Res (2006) 0.93
Update on Chagas heart disease on the first centenary of its discovery. Rev Esp Cardiol (2009) 0.92
Involvement of Ssp-4-related carbohydrate epitopes in mammalian cell invasion by Trypanosoma cruzi amastigotes. Microbes Infect (2006) 0.91
Non-conventional flow cytometry approaches to detect anti-Trypanosoma cruzi immunoglobulin G in the clinical laboratory. J Immunol Methods (2006) 0.89
Long-term follow-up of implantable cardioverter-defibrillator for secondary prevention in chagas' heart disease. Am J Cardiol (2012) 0.87
Specific treatment for Trypanosoma cruzi: lack of efficacy of allopurinol in the human chronic phase of Chagas disease. Am J Trop Med Hyg (2007) 0.84
Applicability of an optimized non-conventional flow cytometry method to detect anti-Trypanosoma cruzi immunoglobulin G for the serological diagnosis and cure assessment following chemotherapeutic treatment of Chagas disease. J Immunol Methods (2011) 0.82
Double-blind study to evaluate flow cytometry analysis of anti-live trypomastigote antibodies for monitoring treatment efficacy in cases of human Chagas' disease. Clin Diagn Lab Immunol (2002) 0.82
[Congenital transmission of Trypanosoma cruzi in Brazil: estimation of prevalence based on preliminary data of national serological surveys in children under 5 years old and other sources]. Rev Soc Bras Med Trop (2005) 0.82
[Correlation among the positivity of the artificial xenodiagnosis and the amount of blood and triatomines used in the exam, in chronic chagasic patients]. Rev Soc Bras Med Trop (2002) 0.81
Implantable cardioverter-defibrillators in patients with Chagas heart disease: misperceptions, many questions and the urgent need for a randomized clinical trial. J Cardiovasc Electrophysiol (2007) 0.77
[Optimization of the medical treatment in coronary artery disease: a task for the subspecialist?]. Arq Bras Cardiol (2004) 0.77
A Latin American man with palpitations, dizziness, episodes of nonsustained ventricular tachycardia, and an apical aneurysm. PLoS Negl Trop Dis (2011) 0.76
Predicting prognosis in patients with Chagas disease: why are the results of various studies so different? Int J Cardiol (2009) 0.75
[Evaluation of blood tests, complement-mediated lysis and polymerase chain reaction in the verification of therapeutic efficacy in Chagas disease]. Rev Soc Bras Med Trop (2006) 0.75
Letter by Rassi et al regarding article, "Beta-blocker therapy and mortality of patients with Chagas cardiomyopathy: a subanalysis of the REMADHE prospective trial". Circ Heart Fail (2010) 0.75
Case 2-2010: a man with abdominal and flank pain. N Engl J Med (2010) 0.75
Is reclassification of intermediate-risk subjects by coronary artery calcium scoring clinically useful? J Am Coll Cardiol (2011) 0.75
Preventing type 2 diabetes mellitus with angiotensin blockade: is it clinically relevant? J Am Coll Cardiol (2006) 0.75
Prognostic utility of coronary computed tomography angiography: are we looking at the correct outcomes and making appropriate comparisons? JACC Cardiovasc Imaging (2009) 0.75
[Cardiovascular magnetic resonance and computed tomography imaging guidelines of the Brazilian Society of Cardiology]. Arq Bras Cardiol (2006) 0.75
Economic analysis of drug-eluting coronary stents in Brazil: a choice for all or just for a few patients? Arq Bras Cardiol (2007) 0.75